Evaluation of glucose metabolism, endocrine, and renal functions following vaccination in post-COVID-19 individuals: a longitudinal retrospective single-center cohort study Authors: Ceren Gür, Sezen Kumaş Solak Published: 2025 ABSTRACT BackgroundThe coronavirus disease 2019 (COVID-19) affects multiple body systems, causing lasting effects on metabolic, endocrine, renal, and hematological functions. While vaccination is known to lessen the severity of acute disease, its long-term effects on biochemical and physiological markers are not well understood. This study aimed to assess the 30-month longitudinal changes in key clinical biomarkers in COVID-19 survivors, categorized by their vaccination status.MethodsThis retrospective single-center cohort study involved 421 adult patients with PCR-confirmed COVID-19, divided into three groups: unvaccinated (Group-1), partially vaccinated with 1–2 doses (Group-2), and fully vaccinated with ≥ 3 doses (Group-3). Smokers were excluded. Laboratory data were recorded at four intervals: baseline (T0), 18 months (T1), 24 months (T2), and 30 months (T3). COVID-19 patients were evaluated for metabolic, endocrine, hematologic, renal, cardiac, and coagulation markers, stratified by vaccination status.ResultsGroup-3 showed improvements in fasting glucose (from 127.00 ± 3.87 to 113.20 ± 2.69 mg/dL; P = 0.0061) and hemoglobin A1c (from 7.06 ± 0.22% to 6.43 ± 0.14%, P = 0.0075), reduced C-reactive protein (CRP) levels (from 13.23 ± 2.04 to 7.06 ± 0.97 mg/dL; P = 0.0183), and stable hypertension prevalence. Thyroid-stimulating hormone (TSH) and thyroxine (T4) levels increased slightly in Group-3, suggesting potential immunomodulation of the thyroid axis, while triiodothyronine (T3) levels remained stable. Creatinine levels increased significantly over time only in Group-3 (from 0.85 ± 0.03 to 0.94 ± 0.04 mg/dL; P = 0.0018) but remained within reference limits and were positively correlated with age and vaccine dose. No significant changes were observed in lipid profile, D-dimer, fibrinogen, or troponin levels at T3 across groups. Conversely, unvaccinated individuals experienced ongoing glycemic dysregulation and an increase in hypertension prevalence (from 23.7% to 72.9%, P < 0.0001).ConclusionsFull COVID-19 vaccination may be linked with improved long-term outcomes in glucose regulation and cardiovascular stability. These findings support enhancing clinical follow-up and public health practices and suggest that vaccination may be associated with improved metabolic profiles in long-term follow-up for COVID-19 survivors.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12179-5. Background The coronavirus disease (COVID-19), which emerged in 2019 and became a global pandemic, is now understood to be a systemic infection that can impact various body systems including the respiratory, cardiovascular, renal, endocrine, hematological, and immune systems, leading to multiple organ dysfunction [1–3]. The pathogenesis of the SARS-CoV-2 virus involves mechanisms such as cytokine storm, cellular immune response disorders, endothelial dysfunction, and coagulation system imbalances. Additionally, beyond the acute infection phase, the clinical picture called “prolonged COVID” or “post-acute COVID-19 syndrome”, in which symptoms persist for an extended period, potentially resulting in long-term health issues [4]. Common laboratory parameters play an important role in assisting the detection of COVID-19 cases. Metabolic, hormonal, and inflammatory disorders observed during the post-infection period serve as essential indicators for predicting the severity of the disease and potential complications. Specifically, SARS-CoV-2 infection has been reported to induce disruptions in glucose metabolism (hyperglycemia) [5], reductions in renal function (elevated urea and creatinine levels) [6], thyroid hormone imbalances (alterations in thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4) levels) [7], and dyslipidemia (elevated total cholesterol and triglyceride levels) [8]. Furthermore, an increase in troponin levels, a cardiac biomarker, is indicative of myocardial damage [9]. Elevated D-dimer and fibrinogen levels, which suggest coagulopathy, are significant outcomes of vascular inflammation associated with COVID-19 [10]. Additionally, variations in C-reactive protein (CRP), white blood count (WBC), neutrophil (NEU) count, and lymphocyte (LY) count are regarded as direct indicators of systemic inflammation [11]. Clinical blood biomarkers after infection vary based on immune status, disease severity, and vaccination. COVID-19 vaccines help prevent infection, reduce disease severity, lower mortality, and mitigate systemic complications. Particularly, mRNA (Pfizer-BioNTech, and Moderna) and inactivated (Sinovac) vaccines induce immune memory that reduces the severity of acute disease and suppresses long-term inflammation [12, 13]. Research indicates that vaccination may influence not only clinical outcomes but also biochemical and hematological parameters. Studies have reported that mRNA-based COVID-19 vaccines may cause short-term, mild increases in inflammatory markers such as CRP and fibrinogen. These changes typically normalize within a few days and do not result in a significant increase in long-term systemic inflammatory burden [14, 15]. Additionally, Furer, et al. [16] highlighted that the BNT162b2 vaccine is safe for individuals with autoimmune diseases and helps stabilize systemic inflammation parameters. Studies suggest that treatments and vaccination (especially, three or more vaccines) may attenuate the clinical course of COVID-19 and exhibit better-balanced inflammatory and metabolic markers, as well as a more durable immune response. Conversely, unvaccinated individuals or those with only one or two doses often experience prolonged inflammation and abnormal blood parameters [17, 18]. There is currently limited information available regarding long-term outcomes in vaccinated populations. This retrospective cohort study investigates the impact of vaccination status on biomarker levels in COVID-19 survivors in Istanbul/Türkiye, aiming to enhance clinical follow-up and inform public health practices. Participants were categorized by vaccination status: (1) unvaccinated, (2) received 1–2 doses, and (3) received three or more doses. Smoking was excluded as a criterion due to its potential impact on inflammation and vascular stress, aiming to allow for a more reliable and vaccination status-specific evaluation [19]. This study is among the few that examine post-infection alterations in biomarkers (including glucose, hemoglobin A1C, creatinine, urea, TSH, T3, T4, total cholesterol, triglycerides, D-dimer, troponin, fibrinogen, CRP, WBC, NEU count, and LY count) concerning vaccination status, thereby informing prolonged COVID management and vaccination policies. To facilitate future studies and long-term clinical follow-up, this work advances current knowledge by presenting 30-month longitudinal trajectories in an integrated framework that jointly tracks endocrine and renal markers alongside metabolic, inflammatory, and cardiac indices. Methods Research methodology, context, and participants Our research is a retrospective, mono-centered study. This report was designed to investigate the longitudinal changes in selected biochemical, hormonal, hematological, and inflammatory biomarkers in individuals previously diagnosed with COVID-19, with stratification based on vaccination status. Figure 1 presents the flowchart depicting the study design and steps. Fig. 1Flowchart outlining the study design and steps Flowchart outlining the study design and steps The study was conducted at the COVID-19 Ward of Bağcılar Training and Research Hospital, University of Health Sciences in Istanbul, Türkiye. Adult patients (≥ 18 years) exhibited symptoms consistent with COVID-19, such as sudden onset of high fever, cough, and dyspnea, were admitted to the clinics. All patients underwent a polymerase chain reaction (PCR) test using a nasal–throat swab, confirming SARS-CoV-2 infection according to WHO criteria [20], and received treatment from January 2020 to December 2022. Participants with missing laboratory data at any time point (T0-T3) were not included in this on-court study, complete case analyzes were performed. To reduce confounding factors and maintain consistent follow-up, our study exclusion criteria were as follows: (i) history of diabetes mellitus (DM), (ii) history of hypertension (HT), (iii) history of chronic renal disease, (iv) immunocompromised status (e.g., active chemotherapy, advanced immunodeficiency), (v) severe comorbidities expected to markedly affect study biomarkers (e.g., end-stage organ failure), (vi) age < 18 years, (vii) pregnancy or lactation, (viii) active malignancy, (ix) cognitive impairment precluding informed participation, (x) absence of consent, and (xi) physical or mental incapacity to participate. After applying these criteria, 499 patients who underwent three follow-ups within 30 months in the province of Istanbul, Türkiye. Next, we excluded the 31 active smokers and 47 former smokers to avoid smoking-related confounding factors. The final cohort of 421 patients was divided into three groups based on COVID-19 vaccination status. Vaccination information, including dose numbers and vaccine types (mRNA-based “BioNTech” or inactivated “SINOVAC”), were verified through the Turkish National Health Information system and electronic hospital records for accuracy. The groups of this cohort study are as follows: Group-1, unvaccinated (n = 59); Group-2, vaccination: 1–2 doses (n = 137); and Group-3, vaccination: 3–6 doses (n = 225). The sample size was calculated using the G*Power 3.1.9 software (Universität Düsseldorf, Germany). Assuming a medium effect size (Cohen’s f = 0.25), a significance level of α = 0.05, and a total sample size of 421 participants, a post hoc power analysis was conducted. The analysis revealed that the statistical power (1–β) of the study was 0.994. Demographic data and laboratory assessments Demographic data, including age, biological sex, and body mass index (BMI), were collected from hospital records at the first admission (T0). BMI was calculated from weight and height data (= Weight [kg]/Height2 [m2]). These characteristics ensured intergroup comparability and assessed potential confounding in biomarker analyses. Venous blood samples were collected at four time points: upon hospital admission (T0), and follow-up at 18 months (T1), 24 months (T2), and 30 months (T3). All laboratory analyses were carried out at the central biochemistry and hematology laboratory of Bağcılar Training and Research Hospital in accordance with standardized clinical protocols and using the same kit and reagents throughout the 30-month study. Serum samples were analyzed using the Roche-Hitachi Cobas 8000 autoanalyzer for measurements including fasting glucose, hemoglobin (Hb)A1c, urea, creatinine, thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), total cholesterol, triglycerides, and low-density lipoprotein (LDL). Inflammatory biomarkers such as C-reactive protein (CRP), fibrinogen, and D-dimer were measured via immunoturbidimetric assays on the Roche Cobas 8000 analyzer according to manufacturer protocols. These assays utilize antigen-antibody complex formation that correlates with analyte concentration, with turbidity assessed photometrically. High-sensitivity cardiac troponin was quantified using a chemiluminescence immunoassay (CLIA) on the same platform, detecting target antigens through antibody binding with a chemiluminescent substrate; the resulting emitted light corresponds to the analyte concentration. Hematological assessments, including total white blood cell (WBC) counts and differential counts for neutrophils (NEU) and lymphocytes (LY), were conducted on EDTA-anticoagulated whole blood using the Mindray- BS-2000 m auto hematology analyzer. Additionally, participants’ blood pressure measurements were documented. Ethical considerations The study protocol was approved by the Ethics Committee of Bağcılar Training and Research Hospital, Istanbul, Türkiye (Approval No: 2025/04/06/038, Approval Date: April 11, 2025) and was conducted according to the Declaration of Helsinki and national research ethics guidelines. This study followed STROBE guidelines and provided a checklist. This work utilized de-identified data, which was provided by patients as part of their routine primary care (all patient data were anonymized to maintain confidentiality). Consent was obtained through an opt-out method, allowing all patients to decline participation. Due to the retrospective nature of the study, the research ethics committee of Bağcılar Training and Research Hospital (Istanbul, Türkiye) waived the need for written informed consent in accordance with institutional requirements. Statistical analysis Statistical analyses were performed using GraphPad Prism Software version 10.5 (La Jolla, California, USA). Data were presented as mean ± standard error of the mean (SEM), medians with interquartile range, and sample sizes (n) with corresponding percentages (%), where appropriate. The Shapiro–Wilk test checked data for normal distribution. Fisher’s exact test assessed categorical variables. The Kruskal–Wallis test was applied when comparing more than two groups, with Dunn’s post-hoc test used for multiple comparisons. Differences between two groups were assessed using the Mann–Whitney U test. The Spearman correlation was employed to evaluate the strength of the association between the two variables. Correlation strengths are as follows: weak (0.20–0.39), moderate (0.40–0.59), strong (0.60–0.79), and very strong (0.80-1.0). Negative (−) r values indicate negative correlations, while positive (+) r values indicate positive correlations. A P-value of less than 0.05 was deemed statistically significant. Results The final study cohort included 421 adult COVID patients. Demographic data of patients including age, gender, BMI, and vaccination type and dose count ​​are presented in Table 1. The study population was divided into three groups: unvaccinated (Group-1, n = 59), partially vaccinated with under three doses (Group-2, n = 137), and fully vaccinated with three or more doses (Group-3, n = 225). The median age was highest in Group-3 (59 years), compared to 51 years in Group-1 and Group-2. The fully vaccinated group had a significantly higher average age (P < 0.0001). BMI values and gender distribution were similar across all groups, with no significant differences (P = 0.9021 and P = 0.1163, respectively). Group-1 included 42.4% males, Group-2 had 41.6%, and Group-3 had 52%. Table 1Demographic data of COVID-19 patientsUnvaccinated (n = 59)Partially vaccinated (1–2 doses) (n = 137)Fully vaccinated (≥ 3 doses) (n = 225)P ValueAge Min-Max (Median) 18–96 (51)19–73 (51)26–80 (59)57.43 ± 0.69< 0.0001*** Mean ± SEM 51.54 ± 1.8650.82 ± 0.87BMI Min-Max (Median) 16.71–39.64 (28.72)20.42–39.79 (30.12)18.37–51.02 (30.10)30.23 ± 0.480.9021 Mean ± SEM 29.39 ± 1.8329.97 ± 0.54Gender Male / n (%) 25 (42.37)57 (41.61)117 (52)0.1163 Female / n (%) 34 (57.63)80 (58.39)108 (48) n Doses # x / y n Doses # x / yVaccine type x = Inactivated vaccine: SINOVAC y = mRNA vaccine: BNT162b2/Comirnaty 51 time2 / 31383 times101 / 3131322 times47 / 217674 times135 / 133175 times59 / 2636 times10 / 8P values ​​(group difference) were obtained using the Kruskal-Wallis test (except for gender, which was analyzed with Fisher’s exact test,# Total administered doses of vaccines x and y. An asterisk indicates a statistically significant difference Table 1Demographic data of COVID-19 patientsUnvaccinated (n = 59)Partially vaccinated (1–2 doses) (n = 137)Fully vaccinated (≥ 3 doses) (n = 225)P ValueAge Min-Max (Median) 18–96 (51)19–73 (51)26–80 (59)57.43 ± 0.69< 0.0001*** Mean ± SEM 51.54 ± 1.8650.82 ± 0.87BMI Min-Max (Median) 16.71–39.64 (28.72)20.42–39.79 (30.12)18.37–51.02 (30.10)30.23 ± 0.480.9021 Mean ± SEM 29.39 ± 1.8329.97 ± 0.54Gender Male / n (%) 25 (42.37)57 (41.61)117 (52)0.1163 Female / n (%) 34 (57.63)80 (58.39)108 (48) n Doses # x / y n Doses # x / yVaccine type x = Inactivated vaccine: SINOVAC y = mRNA vaccine: BNT162b2/Comirnaty 51 time2 / 31383 times101 / 3131322 times47 / 217674 times135 / 133175 times59 / 2636 times10 / 8P values ​​(group difference) were obtained using the Kruskal-Wallis test (except for gender, which was analyzed with Fisher’s exact test,# Total administered doses of vaccines x and y. An asterisk indicates a statistically significant difference Demographic data of COVID-19 patients 26–80 (59) 57.43 ± 0.69 18.37–51.02 (30.10) 30.23 ± 0.48 Vaccine type x = Inactivated vaccine: SINOVAC y = mRNA vaccine: BNT162b2/Comirnaty P values ​​(group difference) were obtained using the Kruskal-Wallis test (except for gender, which was analyzed with Fisher’s exact test, # Total administered doses of vaccines x and y. An asterisk indicates a statistically significant difference Regarding glucose metabolism, Group-3 showed a statistically significant improvement in glycemic parameters over the follow-up period (T0–T3). Mean (± SEM) fasting glucose levels decreased from 127.00 ± 3.87 mg/dL at baseline to 113.2 ± 2.69 mg/dL at T3 (P = 0.0061), while HbA1c levels declined from 7.06 ± 0.22% to 6.43 ± 0.14% (P = 0.0075) (Fig. 2A). These findings may indicate an enhancement in glycemic control among individuals who received three or more doses of the COVID-19 vaccine. Although a downward trend was also observed in Group-2 (individuals with one or two vaccine doses), the degree of change was less pronounced and did not consistently achieve statistical significance (Table 2). Conversely, no significant changes in either fasting glucose or HbA1c levels were observed in Group-1 (unvaccinated individuals), suggesting that the absence of vaccination may be associated with the persistence of post-COVID-19 glycemic dysregulation. Fig. 2Longitudinal changes in metabolic, inflammatory, and endocrine markers of COVID-19 patients. PCR-confirmed individuals categorized into three groups: unvaccinated (Group 1), partially vaccinated with 1–2 doses (Group 2), and fully vaccinated with ≥ 3 doses (Group 3). Laboratory data were recorded at four intervals: baseline (T0), 18 months (T1), 24 months (T2), and 30 months (T3). (A) Glucose and Hemoglobin A1c (HbA1c) levels measured at T0 and T3 timepoints. (B) C-reactive protein (CRP) levels at T3 timepoint across all groups. (C) Thyroid-stimulating hormone (TSH), thyroxine (T4), and triiodothyronine (T3) levels measured at T0 and T3 timepoints. (D) Serum triglycerides, low-density lipoprotein (LDL) and total cholesterol levels measured at T0 and T3 timepoints. The data are presented as mean ± SEM in violin plot graphs. Red-colored P values denote statistically significant findings (P < 0.05). Differences between two groups were assessed using the Mann–Whitney U test. The Spearman correlation was employed to evaluate the strength of the association between the two variables Longitudinal changes in metabolic, inflammatory, and endocrine markers of COVID-19 patients. PCR-confirmed individuals categorized into three groups: unvaccinated (Group 1), partially vaccinated with 1–2 doses (Group 2), and fully vaccinated with ≥ 3 doses (Group 3). Laboratory data were recorded at four intervals: baseline (T0), 18 months (T1), 24 months (T2), and 30 months (T3). (A) Glucose and Hemoglobin A1c (HbA1c) levels measured at T0 and T3 timepoints. (B) C-reactive protein (CRP) levels at T3 timepoint across all groups. (C) Thyroid-stimulating hormone (TSH), thyroxine (T4), and triiodothyronine (T3) levels measured at T0 and T3 timepoints. (D) Serum triglycerides, low-density lipoprotein (LDL) and total cholesterol levels measured at T0 and T3 timepoints. The data are presented as mean ± SEM in violin plot graphs. Red-colored P values denote statistically significant findings (P < 0.05). Differences between two groups were assessed using the Mann–Whitney U test. The Spearman correlation was employed to evaluate the strength of the association between the two variables Table 2Laboratory results on glucose metabolism, thyroid function and lipid profile of COVID-19 patients categorized by vaccination statusUnvaccinated Partially vaccinated (1–2 doses)Fully vaccinated (≥ 3 doses) Min-Max (Median) Min-Max (Median) Min-Max (Median) P Value a Mean ± SEM Mean ± SEM Mean ± SEM Glucose (mg/dL)T077–365 (101)66–384 (102)67–444 (108)0.1546114.40 ± 6.24125.00 ± 4.82127.00 ± 3.87T173–374 (99)72–372 (95)70–504 (101)0.0910119.00 ± 7.85117.80 ± 4.87123.00 ± 3.83T270–328 (100.00)78–287 (98)66–540 (101)0.1845112.10 ± 5.44113.60 ± 3.37120.90 ± 3.71T370–420 (102)64–319 (99)75–355 (102)0.5710123.30 ± 8.89112.80 ± 3.73113.20 ± 2.69 P Value b 0.82400.23810.2647HbA1c (%)T05.70–11.40 (7.65)5.10–13.70 (6.60)5.10–13.70 (6.45)0.13228.33 ± 0.636.37 ± 0.217.06 ± 0.22T15.40–13.40 (6.00)5.00-12.10 (6.20)5.10–12.10 (6.20)0.98917.09 ± 0.536.00 ± 0.137.49 ± 0.15T24.60–12.10 (5.85)4.80–13.70 (6.15)4.80–13.70 (6.20)0.42196.372 ± 0.346.57 ± 0.146.60 ± 0.15T35.60–11.90 (6.10)4.70–12.60 (6.10)5.00-12.60 (5.10)0.65817.03 ± 0.446.43 ± 0.136.43 ± 0.14 P Value b 0.0130*0.0004***0.0091**TSH(µU/mL)T00.17–9.99 (1.72)0.12–10.04 (1.71)0.08–19.90 (1.67)0.88972.06 ± 0.282.11 ± 0.172.03 ± 0.15T10.27–5.79 (1.74)0.13–55.10 (1.80)0.02–8.10 (1.84)0.66882.07 ± 0.172.40 ± 0.452.08 ± 0.09T20.46–6.78 (1.64)0.05–35.80 (1.80)0.07–27.40 (1.92)0.78312.06 ± 0.182.40 ± 0.332.30 ± 0.17T30.01–6.96 (2.04)0.34–75.40 (1.87)0.10–29.10 (1.96)0.81072.53 ± 0.263.05 ± 0.822.58 ± 0.26 P Value b 0.27140.39570.0893T3(ng/L)T02.43–5.34 (3.11)0.55–4.52 (3.09)0.02–5.30 (3.05)0.89083.24 ± 0.143.07 ± 0.073.10 ± 0.06T12.01–3.90 (3.22)1.96–4.15 (3.12)1.43–4.19 (3.03)0.06203.16 ± 0.073.10 ± 0.063.01 ± 0.04T22.03–3.98 (3.06)1.94–4.11 (3.12)1.96–4.45 (3.07)0.46513.04 ± 0.093.13 ± 0.043.06 ± 0.04T32.32–4.10 (3.08)2.03–4.99 (3.55)1.53–3.95 (3.00)0.58043.08 ± 0.093.09 ± 0.072.97 ± 0.05 P Value b 0.64420.80620.4331T4(ng/dL)T00.68–1.73 (1.02)0.79–1.55 (1.15)0.01–2.22 (1.14)0.0237*1.07 ± 0.041.15 ± 0.031.17 ± 0.02T10.72–2.72 (1.13)0.83–1.58 (1.11)0.74–1.98 (1.17)0.11361.18 ± 0.051.12 ± 0.031.21 ± 0.01T20.79–1.55 (1.15)0.67–1.59 (1.14)0.08–1.84 (1.20)0.0290*1.15 ± 0.031.12 ± 0.021.21 ± 0.01T30.83–1.58 (1.10)0.37–2.15 (1.18)0.85–2.36 (1.19)0.0378*1.12 ± 0.031.17 ± 0.021.21 ± 0.02 P Value b 0.09730.73340.1716LDL(mg/dL)T062–190 (121.00)41–216 (114.00)31–271 (117.00)0.7344122.40 ± 5.35119.30 ± 4.45119.70 ± 3.82T158–230 (111.00)40–219 (115.50)34–269 (120.00)0.5993118.10 ± 5.21118.50 ± 3.92121.90 ± 3.18T263–202 (113.50)41–223 (118.00)28–275 (123.00)0.8813120.60 ± 5.14119.00 ± 3.58120.80 ± 3.33T359–233 (111.50)50–192 (113.00)25–234 (120.00)0.8855116.70 ± 5.73116.10 ± 3.88118.20 ± 3.76 P Value b 0.76670.93410.7978Triglyceride (mg/dL)T061-1124 (137.00)41–892 (136.00)46–787 (150.00)0.6926189.60 ± 30.48167.70 ± 12.04179.40 ± 9.64T145–395 (146.00)35–772 (126.00)34–583 (152.00)0.0926163.20 ± 10.94157.310 ± 10.23172.30 ± 6.67T237–448 (132.00)50–602 (144.50)33–531 (143.00)0.8626165.10 ± 13.97174.70 ± 11.17157.90 ± 6.16T344–562 (133.00)52–862 (151.50)48–457 (141.00)0.6010175.00 ± 18.61190.20 ± 14.29160.40 ± 6.68 P Value b 0.95690.23750.3927Total cholesterol(mg/dL)T097–309 (187.00)76–290 (188.00)93–357 (196.00)0.7179193.80 ± 7.75192.40 ± 5.24198.70 ± 4.48T1102–287 (179.50)69–302 (191.00)91–377 (200.00)0.1149185.80 ± 5.46194.00 ± 4.38200.60 ± 3.4T2114–297 (193.00)103–314 (194.00)80–331 (195.00)0.8209194.80 ± 6.14197.30 ± 3.87193.10 ± 3.40T3116–381 (195.00)106–413 (193.00)98–390 (199.00)0.9736201.10 ± 8.49199.40 ± 5.10198.20 ± 4.45 P Value b 0.67340.85180.6984P values ​​were obtained using the Kruskal-Wallis test; a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05, ** P < 0.01, *** P < 0.001 Table 2Laboratory results on glucose metabolism, thyroid function and lipid profile of COVID-19 patients categorized by vaccination statusUnvaccinated Partially vaccinated (1–2 doses)Fully vaccinated (≥ 3 doses) Min-Max (Median) Min-Max (Median) Min-Max (Median) P Value a Mean ± SEM Mean ± SEM Mean ± SEM Glucose (mg/dL)T077–365 (101)66–384 (102)67–444 (108)0.1546114.40 ± 6.24125.00 ± 4.82127.00 ± 3.87T173–374 (99)72–372 (95)70–504 (101)0.0910119.00 ± 7.85117.80 ± 4.87123.00 ± 3.83T270–328 (100.00)78–287 (98)66–540 (101)0.1845112.10 ± 5.44113.60 ± 3.37120.90 ± 3.71T370–420 (102)64–319 (99)75–355 (102)0.5710123.30 ± 8.89112.80 ± 3.73113.20 ± 2.69 P Value b 0.82400.23810.2647HbA1c (%)T05.70–11.40 (7.65)5.10–13.70 (6.60)5.10–13.70 (6.45)0.13228.33 ± 0.636.37 ± 0.217.06 ± 0.22T15.40–13.40 (6.00)5.00-12.10 (6.20)5.10–12.10 (6.20)0.98917.09 ± 0.536.00 ± 0.137.49 ± 0.15T24.60–12.10 (5.85)4.80–13.70 (6.15)4.80–13.70 (6.20)0.42196.372 ± 0.346.57 ± 0.146.60 ± 0.15T35.60–11.90 (6.10)4.70–12.60 (6.10)5.00-12.60 (5.10)0.65817.03 ± 0.446.43 ± 0.136.43 ± 0.14 P Value b 0.0130*0.0004***0.0091**TSH(µU/mL)T00.17–9.99 (1.72)0.12–10.04 (1.71)0.08–19.90 (1.67)0.88972.06 ± 0.282.11 ± 0.172.03 ± 0.15T10.27–5.79 (1.74)0.13–55.10 (1.80)0.02–8.10 (1.84)0.66882.07 ± 0.172.40 ± 0.452.08 ± 0.09T20.46–6.78 (1.64)0.05–35.80 (1.80)0.07–27.40 (1.92)0.78312.06 ± 0.182.40 ± 0.332.30 ± 0.17T30.01–6.96 (2.04)0.34–75.40 (1.87)0.10–29.10 (1.96)0.81072.53 ± 0.263.05 ± 0.822.58 ± 0.26 P Value b 0.27140.39570.0893T3(ng/L)T02.43–5.34 (3.11)0.55–4.52 (3.09)0.02–5.30 (3.05)0.89083.24 ± 0.143.07 ± 0.073.10 ± 0.06T12.01–3.90 (3.22)1.96–4.15 (3.12)1.43–4.19 (3.03)0.06203.16 ± 0.073.10 ± 0.063.01 ± 0.04T22.03–3.98 (3.06)1.94–4.11 (3.12)1.96–4.45 (3.07)0.46513.04 ± 0.093.13 ± 0.043.06 ± 0.04T32.32–4.10 (3.08)2.03–4.99 (3.55)1.53–3.95 (3.00)0.58043.08 ± 0.093.09 ± 0.072.97 ± 0.05 P Value b 0.64420.80620.4331T4(ng/dL)T00.68–1.73 (1.02)0.79–1.55 (1.15)0.01–2.22 (1.14)0.0237*1.07 ± 0.041.15 ± 0.031.17 ± 0.02T10.72–2.72 (1.13)0.83–1.58 (1.11)0.74–1.98 (1.17)0.11361.18 ± 0.051.12 ± 0.031.21 ± 0.01T20.79–1.55 (1.15)0.67–1.59 (1.14)0.08–1.84 (1.20)0.0290*1.15 ± 0.031.12 ± 0.021.21 ± 0.01T30.83–1.58 (1.10)0.37–2.15 (1.18)0.85–2.36 (1.19)0.0378*1.12 ± 0.031.17 ± 0.021.21 ± 0.02 P Value b 0.09730.73340.1716LDL(mg/dL)T062–190 (121.00)41–216 (114.00)31–271 (117.00)0.7344122.40 ± 5.35119.30 ± 4.45119.70 ± 3.82T158–230 (111.00)40–219 (115.50)34–269 (120.00)0.5993118.10 ± 5.21118.50 ± 3.92121.90 ± 3.18T263–202 (113.50)41–223 (118.00)28–275 (123.00)0.8813120.60 ± 5.14119.00 ± 3.58120.80 ± 3.33T359–233 (111.50)50–192 (113.00)25–234 (120.00)0.8855116.70 ± 5.73116.10 ± 3.88118.20 ± 3.76 P Value b 0.76670.93410.7978Triglyceride (mg/dL)T061-1124 (137.00)41–892 (136.00)46–787 (150.00)0.6926189.60 ± 30.48167.70 ± 12.04179.40 ± 9.64T145–395 (146.00)35–772 (126.00)34–583 (152.00)0.0926163.20 ± 10.94157.310 ± 10.23172.30 ± 6.67T237–448 (132.00)50–602 (144.50)33–531 (143.00)0.8626165.10 ± 13.97174.70 ± 11.17157.90 ± 6.16T344–562 (133.00)52–862 (151.50)48–457 (141.00)0.6010175.00 ± 18.61190.20 ± 14.29160.40 ± 6.68 P Value b 0.95690.23750.3927Total cholesterol(mg/dL)T097–309 (187.00)76–290 (188.00)93–357 (196.00)0.7179193.80 ± 7.75192.40 ± 5.24198.70 ± 4.48T1102–287 (179.50)69–302 (191.00)91–377 (200.00)0.1149185.80 ± 5.46194.00 ± 4.38200.60 ± 3.4T2114–297 (193.00)103–314 (194.00)80–331 (195.00)0.8209194.80 ± 6.14197.30 ± 3.87193.10 ± 3.40T3116–381 (195.00)106–413 (193.00)98–390 (199.00)0.9736201.10 ± 8.49199.40 ± 5.10198.20 ± 4.45 P Value b 0.67340.85180.6984P values ​​were obtained using the Kruskal-Wallis test; a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05, ** P < 0.01, *** P < 0.001 Laboratory results on glucose metabolism, thyroid function and lipid profile of COVID-19 patients categorized by vaccination status TSH (µU/mL) T3 (ng/L) T4 (ng/dL) LDL (mg/dL) Total cholesterol (mg/dL) P values ​​were obtained using the Kruskal-Wallis test; a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05, ** P < 0.01, *** P < 0.001 Throughout the follow-up period, a significant temporal decline in CRP levels was seen in both Group-2 and Group-3 (P = 0.0162 and P = 0.0183, respectively), while Group-1 did not exhibit a statistically significant decrease (P = 0.1618) (Table 3). At the final timepoint (T3), no significant differences in CRP levels were observed between the groups (Fig. 2B). Additionally, there were no significant longitudinal changes in hematological parameters, including WBC, NEU, and LY counts, indicating a stable post-recovery immune status regardless of vaccination status (Table 3). Table 3Laboratory results on blood routine and inflammation profile of COVID-19 patients categorized by vaccination statusUnvaccinated Partially vaccinated (1–2 doses)Fully vaccinated (≥ 3 doses) Min-Max (Median) Min-Max (Median) Min-Max (Median) P Value a Mean ± SEM Mean ± SEM Mean ± SEM CRP (mg/dL)T10.26–132.50 (3.49)0.24–170.60 (4.40)0.02–309.80 (3.94)0.646012.90 ± 3.3714.27 ± 2.4713.23 ± 2.04T20.39–112.50 (2.36)0.27–245.40 (3.01)0.27–276.70 (3.35)0.34565.20 ± 1.899.43 ± 2.266.61 ± 1.31T30.08–83.53 (2.97)0.21–64.17 (3.17)0.25–146.60 (2.97)0.97356.44 ± 1.615.35 ± 0.707.06 ± 0.97 P Value b 0.16180.0162*0.0183*WBC Count (×109/L)T12.84–15.90 (6.94)1.76–11.51 (6.75)0.88–20.13 (6.87)0.60177.09 ± 0.266.89 ± 0.167.28 ± 0.17T23.58–14.01 (6.74)3.95–18.08 (6.95)3.34–24.42 (6.76)0.55897.15 ± 0.277.34 ± 0.197.11 ± 0.15T33.80-11.77 (6.65)3.41–13.29 (6.79)2.69–20.36 (6.94)0.45046.90 ± 0.227.17 ± 0.167.32 ± 0.16 P Value b 0.77150.32650.5490NEU Count (×10³/µL)T138.30–88.30 (61.90)36.30–90.70 (59.20)5.87–93.40 (60.30)0.065162.60 ± 1.3459.58 ± 0.7760.65 ± 0.74T236.20–87.30 (59.60)37.80–91.20 (59.00)5.49–86.40 (58.70)0.859759.75 ± 1.3459.29 ± 0.8458.93 ± 0.63T327.70–87.70 (59.40)37.80–84.90 (57.90)19.90–90.40 (58.65)0.486058.70 ± 1.2558.20 ± 0.7459.36 ± 0.62 P Value b 0.05450.51850.2161LY Count (%)T19.70–53.30 (28.30)5.70–53.80 (30.60)2.30–76.40 (29.30)0.146128.66 ± 1.1830.76 ± 0.7229.52 ± 0.64T26.30–52.90 (32.30)6.20–55.70 (31.10)7.20–72.50 (30.90)0.670531.52 ± 1.2131.52 ± 0.7431.12 ± 0.56T310.20–52.90 (31.40)9.40–60.10 (31.40)7.40–78.00 (31.40)0.366731.76 ± 1.0732.24 ± 0.7230.85 ± 0.60 P Value b 0.0436*0.40760.1267P values ​​were obtained using the Kruskal-Wallis test; a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05 Table 3Laboratory results on blood routine and inflammation profile of COVID-19 patients categorized by vaccination statusUnvaccinated Partially vaccinated (1–2 doses)Fully vaccinated (≥ 3 doses) Min-Max (Median) Min-Max (Median) Min-Max (Median) P Value a Mean ± SEM Mean ± SEM Mean ± SEM CRP (mg/dL)T10.26–132.50 (3.49)0.24–170.60 (4.40)0.02–309.80 (3.94)0.646012.90 ± 3.3714.27 ± 2.4713.23 ± 2.04T20.39–112.50 (2.36)0.27–245.40 (3.01)0.27–276.70 (3.35)0.34565.20 ± 1.899.43 ± 2.266.61 ± 1.31T30.08–83.53 (2.97)0.21–64.17 (3.17)0.25–146.60 (2.97)0.97356.44 ± 1.615.35 ± 0.707.06 ± 0.97 P Value b 0.16180.0162*0.0183*WBC Count (×109/L)T12.84–15.90 (6.94)1.76–11.51 (6.75)0.88–20.13 (6.87)0.60177.09 ± 0.266.89 ± 0.167.28 ± 0.17T23.58–14.01 (6.74)3.95–18.08 (6.95)3.34–24.42 (6.76)0.55897.15 ± 0.277.34 ± 0.197.11 ± 0.15T33.80-11.77 (6.65)3.41–13.29 (6.79)2.69–20.36 (6.94)0.45046.90 ± 0.227.17 ± 0.167.32 ± 0.16 P Value b 0.77150.32650.5490NEU Count (×10³/µL)T138.30–88.30 (61.90)36.30–90.70 (59.20)5.87–93.40 (60.30)0.065162.60 ± 1.3459.58 ± 0.7760.65 ± 0.74T236.20–87.30 (59.60)37.80–91.20 (59.00)5.49–86.40 (58.70)0.859759.75 ± 1.3459.29 ± 0.8458.93 ± 0.63T327.70–87.70 (59.40)37.80–84.90 (57.90)19.90–90.40 (58.65)0.486058.70 ± 1.2558.20 ± 0.7459.36 ± 0.62 P Value b 0.05450.51850.2161LY Count (%)T19.70–53.30 (28.30)5.70–53.80 (30.60)2.30–76.40 (29.30)0.146128.66 ± 1.1830.76 ± 0.7229.52 ± 0.64T26.30–52.90 (32.30)6.20–55.70 (31.10)7.20–72.50 (30.90)0.670531.52 ± 1.2131.52 ± 0.7431.12 ± 0.56T310.20–52.90 (31.40)9.40–60.10 (31.40)7.40–78.00 (31.40)0.366731.76 ± 1.0732.24 ± 0.7230.85 ± 0.60 P Value b 0.0436*0.40760.1267P values ​​were obtained using the Kruskal-Wallis test; a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05 Laboratory results on blood routine and inflammation profile of COVID-19 patients categorized by vaccination status P values ​​were obtained using the Kruskal-Wallis test; a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05 Thyroid hormone levels showed selective alteration across the study groups. At the T3 timepoint, thyroid dysfunction, including both hypo- and hyperthyroidism, was identified in 8.47% of individuals in Group-1, 6.57% in Group-2, and 5.33% in Group-3, using a reference TSH range of 0.5–5.0 µU/mL according to established clinical guidelines [21, 22]. A mild but statistically significant increase in serum TSH levels was noted exclusively in Group-3 (P = 0.0251) (Fig. 2C), with mean concentrations reaching 2.58 ± 0.26 µU/mL at T3. Despite the observed elevation, TSH values remained within clinically accepted reference ranges. T3 levels showed no significant changes in any group, while a mild but statistically significant increase in T4 levels was noted between groups at T0, T2, and T3 (P = 0.0237, P = 0.0290, and P = 0.0378, respectively) (Table 2). However, comparing baseline (T0) to final (T3) measurements, no significant differences were found overall (Fig. 2C). The slight changes observed in Group-3 individuals may suggest regulation in thyroid-related parameters. Additionally, total cholesterol, triglyceride, and LDL concentrations did not show significant changes across all groups and time points (P >0.2) (Table 2). Similarly, within-group comparisons between T0 and T3 values revealed no notable changes in these parameters (Fig. 2D). Serum urea and creatinine are widely accepted parameters to evaluate renal function [23], and these variations indicate differences in how kidney function was impacted among the groups. Serum creatinine levels differed significantly between groups at each timepoint (T0, T1, T2, and T3; P = 0.0125, P = 0.0009, P = 0.0016, and P = 0.0008) (Table 4). Only Group-3 showed a significant increase from T0 to T3 (Fig. 3A). Serum urea levels remained stable without significant changes across all groups (Table 4). Creatinine levels had a weak positive correlation with the number of vaccine doses (r = 0.21, P < 0.0001) and age (r = 0.29, P < 0.0001), indicating an age- and vaccination-related trend in renal function markers (Fig. 3B). Table 4Laboratory results on renal, cardiac and coagulation parameters of COVID-19 patients categorized by vaccination statusUnvaccinated Partially vaccinated (1–2 doses)Fully vaccinated (≥ 3 doses) Min-Max (Median) Min-Max (Median) Min-Max (Median) P Value a Mean ± SEM Mean ± SEM Mean ± SEM Urea(mg/dL)T012.50-102.30 (28.80)11.80-112.80 (29.10)14.10–132.00 (30.70)0.188134.67 ± 2.4132.18 ± 1.2834.61 ± 1.07T111.40-110.10 (29.20)11.70-101.90 (28.25)16.20-114.50 (30.40)0.095835.32 ± 2.7231.21 ± 1.1833.44 ± 0.90T211.00-93.40 (30.20)11.70–97.40 (28.05)14.00-163.60 (30.20)0.135434.60 ± 2.2731.06 ± 1.0934.67 ± 1.26T315.00-97.40 (29.25)15.70–94.60 (30.20)14.20–176.00 (30.10)0.709133.68 ± 2.4632.12 ± 1.1034.30 ± 1.32 P Value b 0.90510.67750.9763Creatinine(mg/dL)T00.35–3.24 (0.71)0.37–6.87 (0.71)0.34–4.56 (0.77)0.0125*0.86 ± 0.070.80 ± 0.050.85 ± 0.03T10.40–3.50 (0.74)0.31–7.1 (0.73)0.42–4.35 (0.80)0.0009***0.90 ± 0.070.82 ± 0.050.89 ± 0.03T20.42–3.14 (0.73)0.33–4.26 (0.72)0.40–4.68 (0.82)0.0016**0.87 ± 0.070.81 ± 0.030.92 ± 0.04T30.44–3.01 (0.71)0.35–3.54 (0.78)0.37–4.72 (0.84)0.0008***0.88 ± 0.070.85 ± 0.040.94 ± 0.04 P Value b 0.77960.11290.0020**D-dimer (µg/mL)T10.03–2.90 (0.26)0.01–7.99 (0.25)0.01–8.78 (0.31)0.26900.44 ± 0.080.58 ± 0.100.64 ± 0.08T20.00-9.74 (0.31)0.01–6.98 (0.24)0.01–5.56 (0.32)0.62330.55 ± 0.190.41 ± 0.060.46 ± 0.04T30.06–2.19 (0.32)0.01–1.71 (0.30)0.07–12.50 (0.31)0.82680.45 ± 0.080.34 ± 0.030.47 ± 0.09 P Value b 0.59450.0487*0.3079Fibrinogen(mg/dL)T1232–721 (432.00)94–786 (411.00)238–935 (433.00)a 0.5649453.40 ± 15.79435.80 ± 11.28453.20 ± 9.17T2186–654 (376.00)205–736 (397.50)168–697 (399.00)a 0.6605400.90 ± 13.33397.50 ± 8.86403.40 ± 6.65T3227–566 (329.00)255–639 (389.10)189–685 (380.50)a 0.0508359.10 ± 15.20389.10 ± 8.33394.50 ± 8.27 P Value b 0.0002***0.0032**<0.0001***Troponin(pg/mL)T10-301.40 (6.15)0-73.82 (3.33)0-318.10 (4.60)a 0.195514.87 ± 7.846.38 ± 1.159.78 ± 2.59T21.70-61.46 (4.52)0-120.50 (4.07)1.17–261.00 (5.13)a 0.52148.28 ± 2.5511.13 ± 3.1912.22 ± 3.41T32.30-77.66 (5.89)2.10-89.82 (6.05)1.00-62.21 (6.65)a 0.513210.06 ± 3.308.98 ± 2.339.87 ± 1.34 P Value b 0.38380.0073**0.0034** Yes / n (%) Yes / n (%) Yes / n (%) P Value a No / n (% No / n (% No / n (% Hypertension (HT)T014 (23.73)38 (27.74)103 (45.78)< 0.0001***45 (76.27)99 (72.26)122 (54.22)T343 (72.88)42 (30.66)108 (48.00)0.0002***16 (27.12)95 (69.34)117 (52.00) P Value b < 0.0001***0.69030.7056P values were obtained using the Kruskal-Wallis test (except for HT, which was analyzed with Fisher’s exact test); a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05, ** P < 0.01, *** P < 0.001 Table 4Laboratory results on renal, cardiac and coagulation parameters of COVID-19 patients categorized by vaccination statusUnvaccinated Partially vaccinated (1–2 doses)Fully vaccinated (≥ 3 doses) Min-Max (Median) Min-Max (Median) Min-Max (Median) P Value a Mean ± SEM Mean ± SEM Mean ± SEM Urea(mg/dL)T012.50-102.30 (28.80)11.80-112.80 (29.10)14.10–132.00 (30.70)0.188134.67 ± 2.4132.18 ± 1.2834.61 ± 1.07T111.40-110.10 (29.20)11.70-101.90 (28.25)16.20-114.50 (30.40)0.095835.32 ± 2.7231.21 ± 1.1833.44 ± 0.90T211.00-93.40 (30.20)11.70–97.40 (28.05)14.00-163.60 (30.20)0.135434.60 ± 2.2731.06 ± 1.0934.67 ± 1.26T315.00-97.40 (29.25)15.70–94.60 (30.20)14.20–176.00 (30.10)0.709133.68 ± 2.4632.12 ± 1.1034.30 ± 1.32 P Value b 0.90510.67750.9763Creatinine(mg/dL)T00.35–3.24 (0.71)0.37–6.87 (0.71)0.34–4.56 (0.77)0.0125*0.86 ± 0.070.80 ± 0.050.85 ± 0.03T10.40–3.50 (0.74)0.31–7.1 (0.73)0.42–4.35 (0.80)0.0009***0.90 ± 0.070.82 ± 0.050.89 ± 0.03T20.42–3.14 (0.73)0.33–4.26 (0.72)0.40–4.68 (0.82)0.0016**0.87 ± 0.070.81 ± 0.030.92 ± 0.04T30.44–3.01 (0.71)0.35–3.54 (0.78)0.37–4.72 (0.84)0.0008***0.88 ± 0.070.85 ± 0.040.94 ± 0.04 P Value b 0.77960.11290.0020**D-dimer (µg/mL)T10.03–2.90 (0.26)0.01–7.99 (0.25)0.01–8.78 (0.31)0.26900.44 ± 0.080.58 ± 0.100.64 ± 0.08T20.00-9.74 (0.31)0.01–6.98 (0.24)0.01–5.56 (0.32)0.62330.55 ± 0.190.41 ± 0.060.46 ± 0.04T30.06–2.19 (0.32)0.01–1.71 (0.30)0.07–12.50 (0.31)0.82680.45 ± 0.080.34 ± 0.030.47 ± 0.09 P Value b 0.59450.0487*0.3079Fibrinogen(mg/dL)T1232–721 (432.00)94–786 (411.00)238–935 (433.00)a 0.5649453.40 ± 15.79435.80 ± 11.28453.20 ± 9.17T2186–654 (376.00)205–736 (397.50)168–697 (399.00)a 0.6605400.90 ± 13.33397.50 ± 8.86403.40 ± 6.65T3227–566 (329.00)255–639 (389.10)189–685 (380.50)a 0.0508359.10 ± 15.20389.10 ± 8.33394.50 ± 8.27 P Value b 0.0002***0.0032**<0.0001***Troponin(pg/mL)T10-301.40 (6.15)0-73.82 (3.33)0-318.10 (4.60)a 0.195514.87 ± 7.846.38 ± 1.159.78 ± 2.59T21.70-61.46 (4.52)0-120.50 (4.07)1.17–261.00 (5.13)a 0.52148.28 ± 2.5511.13 ± 3.1912.22 ± 3.41T32.30-77.66 (5.89)2.10-89.82 (6.05)1.00-62.21 (6.65)a 0.513210.06 ± 3.308.98 ± 2.339.87 ± 1.34 P Value b 0.38380.0073**0.0034** Yes / n (%) Yes / n (%) Yes / n (%) P Value a No / n (% No / n (% No / n (% Hypertension (HT)T014 (23.73)38 (27.74)103 (45.78)< 0.0001***45 (76.27)99 (72.26)122 (54.22)T343 (72.88)42 (30.66)108 (48.00)0.0002***16 (27.12)95 (69.34)117 (52.00) P Value b < 0.0001***0.69030.7056P values were obtained using the Kruskal-Wallis test (except for HT, which was analyzed with Fisher’s exact test); a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05, ** P < 0.01, *** P < 0.001 Laboratory results on renal, cardiac and coagulation parameters of COVID-19 patients categorized by vaccination status Urea (mg/dL) Creatinine (mg/dL) Fibrinogen (mg/dL) Troponin (pg/mL) P values were obtained using the Kruskal-Wallis test (except for HT, which was analyzed with Fisher’s exact test); a: group difference at the same time point, b: difference between time. An asterisk indicates a statistically significant difference; * P < 0.05, ** P < 0.01, *** P < 0.001 Fig. 3Longitudinal changes in renal and coagulation biomarkers of COVID-19 patients. PCR-confirmed individuals categorized into three groups: unvaccinated (Group 1), partially vaccinated with 1–2 doses (Group 2), and fully vaccinated with ≥ 3 doses (Group 3). Laboratory data were recorded at four intervals: baseline (T0), 18 months (T1), 24 months (T2), and 30 months (T3). (A) Serum urea and creatinine levels measured at T0 and T3 timepoints. (B) Spearman correlation analyses of urea and creatinine levels with the number of vaccinations (left), and only creatinine with age and Body mass index (BMI, right). (C) Troponin, D-dimer, and fibrinogen levels measured at T0 and T3 timepoints. (D) Spearman correlation analyses of D-dimer and fibrinogen levels with the number of vaccinations. The data are presented as mean ± SEM in violin plot graphs. Red-colored P values denote statistically significant findings (P < 0.05). Differences between two groups were assessed using the Mann–Whitney U test. The Spearman correlation was employed to evaluate the strength of the association between the two variables Longitudinal changes in renal and coagulation biomarkers of COVID-19 patients. PCR-confirmed individuals categorized into three groups: unvaccinated (Group 1), partially vaccinated with 1–2 doses (Group 2), and fully vaccinated with ≥ 3 doses (Group 3). Laboratory data were recorded at four intervals: baseline (T0), 18 months (T1), 24 months (T2), and 30 months (T3). (A) Serum urea and creatinine levels measured at T0 and T3 timepoints. (B) Spearman correlation analyses of urea and creatinine levels with the number of vaccinations (left), and only creatinine with age and Body mass index (BMI, right). (C) Troponin, D-dimer, and fibrinogen levels measured at T0 and T3 timepoints. (D) Spearman correlation analyses of D-dimer and fibrinogen levels with the number of vaccinations. The data are presented as mean ± SEM in violin plot graphs. Red-colored P values denote statistically significant findings (P < 0.05). Differences between two groups were assessed using the Mann–Whitney U test. The Spearman correlation was employed to evaluate the strength of the association between the two variables Cardiac biomarkers, including troponin, D-dimer, and fibrinogen, are well-established clinical indicators of myocardial injury, coagulation status, and cardiovascular risk, particularly in the context of systemic inflammation and post-viral syndromes [1, 24]. Temporal changes in troponin levels reached statistical significance in both Group-2 (P = 0.0073) and Group-3 (P = 0.0034) (Table 4). However, no significant differences in troponin levels were observed between the groups at the T3 timepoint (Fig. 3C). D-dimer levels showed a substantial change over time only in Group-2 (P = 0.0487), whereas fibrinogen levels demonstrated marked alterations across all three groups (P = 0.0002 for Group-1, P = 0.0032 for Group-2, and P < 0.0001 for Group-3) (Table 4). Neither D-dimer nor fibrinogen levels differed significantly between the groups at T3 (Fig. 3C). Correlation analyses revealed no significant association between the number of vaccine doses and either D-dimer or fibrinogen levels (Fig. 3D). Additionally, the prevalence of hypertension increased significantly in Group-1, rising from 23.7% at T0 to 72.9% at T3 (P < 0.0001). In contrast, hypertension rates in Group-2 and Group-3 remained relatively stable over time, reaching 30.7% and 48.0%, respectively, at T3 timepoint (Table 4). The findings indicate that COVID-19 vaccination may help prevent long-term cardiovascular complications after the acute phase of the disease. Discussion Current health guidance defines full COVID-19 vaccination as completing the primary series plus at least one booster dose, with three or more doses indicating full immunization for long-term outcomes [12, 25]. This retrospective single-cohort study provides comprehensive longitudinal insights into the metabolic, endocrine, renal, and hematologic sequelae in recovered COVID-19 patients, categorized by their vaccination status. The analysis, conducted over a 30-month period, identifies the potential protective effects of full vaccination (≥ 3 doses) on reducing persistent post-acute physiological issues. One notable observation of this study is the apparent improvement in glycemic control among fully vaccinated individuals (Group-3), as evidenced by a gradual reduction in both fasting glucose and HbA1c levels over time. This trend aligns with recent research indicating that COVID-19 vaccination may help mitigate post-viral metabolic dysregulation, potentially by modulating systemic inflammation and restoring insulin sensitivity [26–28]. Consistent with this mechanism, fully vaccinated individuals are more likely to experience milder acute disease and reduced exposure to systemic glucocorticoids, limiting steroid-related hyperglycemia [29]; recovery-phase behavioral normalization (diet and physical activity) and closer outpatient follow-up may further reinforce these improvements [30]. Apart from vaccination, improvements in glucose metabolism after COVID-19 may also result from factors like proper nutrition, diabetes management, lifestyle, and exercise [31]. On the other hand, unvaccinated individuals (Group-1) in the present study did not exhibit any significant improvements in glycemic parameters, supporting earlier hypotheses that SARS-CoV-2 infection can cause prolonged beta-cell stress or promote insulin resistance, particularly in vulnerable populations [32]. Moreover, Nishida, et al. [33] found that glucose control in individuals with diabetes remained stable or even improved after receiving the COVID-19 vaccination. Besides, post-COVID-19 dysglycemia has been shown to be associated not only with vaccination status, but also, though less significantly, with factors such as BMI and lipid profile [34]. These findings suggest that complete COVID-19 vaccination may offer potential metabolic benefits, in addition to protection against severe illness. Nevertheless, additional studies are necessary to validate and elucidate the mechanisms responsible for these effects. Initial measurements of CRP, an essential acute-phase reactant, in our hospitalized SARS-CoV-2 patients were highly elevated; this is supported by the observation that pooled CRP levels in a meta-analysis including both severe and non-severe cases were lower than the T0 measurements of our total cohort [11]. Notably, CRP levels exhibited a significant temporal decline in vaccinated individuals, while no significant change was observed in the unvaccinated cohort. This trend may suggest a potential role for COVID-19 vaccination in reducing chronic, low-grade inflammation, which has been implicated in the pathophysiology of long COVID and an increased cardiometabolic risk [35, 36]. Supportively, Ali, et al. [37] reported that hospitalized COVID-19 patients with severe outcomes had significantly higher CRP levels, especially non-survivors, while CRP levels normalized during recovery in survivors. The absence of persistent CRP elevation in vaccinated groups may suggest effective resolution of systemic inflammation after infection. Additionally, stable WBC, NEU, and LY counts across all groups indicate no ongoing hematologic disruption and suggest immunological recovery, regardless of vaccination status. The studies in COVID-19 populations indicate that TSH, T3, and T4 values are similar to those observed in our cohort at T0 measurements [7, 38]. Notably, fully vaccinated individuals showed a distinct endocrine pattern, characterized by a modest but significant increase in TSH and T4 levels. Despite all values being within reference ranges, this trend may indicate a subtle rebalancing of the hypothalamic-pituitary-thyroid axis following immunization. Such thyroid axis modulation has previously been linked to immune-mediated neuroendocrine recovery following viral illnesses [39, 40]. The absence of significant changes in free T3 levels further supports the idea that thyroid function remained clinically stable, yet potentially responsive to immune status. Serum urea and creatinine are established indicators of kidney function, reflecting variations in renal function among groups [23]. T0 measurements of serum urea and creatinine levels in our cohort aligned with values reported in prior COVID-19 studies [6, 41]. While serum urea levels remained unchanged, creatinine levels significantly increased over time only in Group-3 (the average remained within normal reference values). Creatinine was positively correlated with both the number of vaccine doses and age, the latter being a known contributor to physiological renal decline [42, 43]. Although this observation may initially raise concerns about renal function post-vaccination, the correlation with age suggests that the effect may be more attributable to demographic factors rather than immunological ones. Cardiac biomarkers like troponin, D-dimer, and fibrinogen assess myocardial injury, coagulation status, and cardiovascular risk, especially in systemic inflammation and post-viral syndromes [1, 24]. Consistent with prior studies, baseline (T0) levels of troponin, D-dimer, and fibrinogen in our cohort were comparable to those reported in COVID-19 populations [9, 10]. Troponin levels exhibited slight but significant fluctuations in Group-2 and Group-3, although no group differences were observed at the final timepoint, indicating subclinical myocardial stress that resolves over time without lasting effects between vaccinated and unvaccinated individuals [44]. Coagulation parameters followed a similar pattern: while D-dimer and fibrinogen levels changed significantly over time in some groups, no differences were found at the T3 timepoint. Besides, no correlation was observed with vaccine dose, suggesting that these fluctuations appear linked to post-COVID recovery rather than vaccination. Another notable finding was the increase in hypertension among the unvaccinated group, while blood pressure remained stable in vaccinated individuals. This supports the hypothesis that COVID-19 vaccination may mitigate long-term cardiovascular complications. Gallo, et al. [45] found persistent endothelial activation and increased arterial stiffness in individuals with a prior SARS-CoV-2 infection, which is associated with a higher cardiovascular risk. Similarly, Xie, et al. [46] reported that individuals infected with SARS-CoV-2 have a higher likelihood of developing cardiovascular conditions such as hypertension, regardless of their vaccination status, pointing to the prolonged vascular consequences of COVID-19. In this context, the fact that there was no rise in hypertension cases among our vaccinated groups may reflect a protective effect conferred by vaccination against post-viral vascular dysregulation. However, further longitudinal studies are warranted to elucidate the underlying mechanisms and confirm these associations across diverse populations. This study has several limitations that should be taken into account when evaluating the results. The retrospective, single-center design limits causal inference and may affect the generalizability of the results to broader or more diverse populations. The lack of pre-infection baseline measurements makes it challenging to identify post-infectious changes from existing physiological variations. Additionally, timing of infection and proinflammatory cytokine data (e.g., IFN-γ, IL-1β, IL-6) were not recorded, limiting mechanistic understanding. Subgroup analysis by vaccine type (inactivated vs. mRNA) was not feasible because of the small sample size, and SARS-CoV-2-specific immune responses were not measured. Besides, the lack of information on SARS-CoV-2 variants prevented detailed analysis. Future research on vaccine types and viral variant subgroups will enhance understanding of the relationship between clinical biomarkers and these subgroups. No participants had documented reinfection either before enrollment or during follow-up. Life quality was not assessed. Data on diet, self-care, and antidiabetic medication were unavailable for individuals with improved glycemic values post-vaccination, limiting conclusions about therapeutic effects. Nonetheless, the study offers key insights into the long-term biochemical and clinical outcomes of COVID-19 recovery, particularly with respect to vaccination status. Given the limited clinical impact of statistically significant results, larger prospective studies are needed. Future multi-center studies incorporating more comprehensive clinical and lifestyle data are necessary to validate and extend these findings. Moreover, future validation of the obtained results in larger, more diverse populations, along with the use of more robust modeling techniques, such as longitudinal or multivariate approaches that better account for demographic and clinical variability, will enhance clinical relevance. Conclusions This retrospective single-cohort study highlights the differential long-term metabolic, endocrine, cardiac, renal, and inflammatory outcomes in individuals infected with SARS-CoV-2, categorized by their vaccination status. Compared to the unvaccinated and partially vaccinated individuals, full vaccination (≥ 3 doses) was associated with improved glycemic control, reduced systemic inflammation, and a stable prevalence of hypertension over a 30-month follow-up period, suggesting a protective role against post-viral cardiometabolic dysregulation. While some fluctuations in renal biomarkers were observed, these changes were generally modest and likely influenced by both age and vaccination status. These findings support enhancing clinical follow-up and public health practices and suggest that comprehensive vaccination not only reduces the severity of acute COVID-19 but may also confer long-term physiological benefits by stabilizing systemic homeostasis in the post-acute phase. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1